炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：智通财经 1、经济数据方面，央行将于2月11日公布中国1月CPI和PPI。国家统计局2月13日将公布1月商品住宅销 售价格指数月度报告。国家统计局2月14日将发布流通领域重要生产资料市场价格变动情况。此外，中 国1月社融、1月新增人民币贷款等金融数据也将于下周公布。 2、国外经济数据方面，美国12月零售销售月率将于2月10日公布。美国1月失业率、美国1月非农就业人 口将于2月11日公布。英国第四季度GDP、美国1月PPI将于2月12日公布。欧元区第四季度GDP、美国1 月CPI将于2月13日公布。 3、美股财报季仍在持续中，下周有多家明星公司发布业绩，2月10日有：英国石油（盘前）、巴克莱银 行（盘前）、万豪酒店（盘前）、可口可乐（盘前）、阿斯利康（盘前）、福特汽车（盘后）、Lyft （盘后）、吉利德科学（盘后）；2月11日有：网易（盘前）、有道（盘前）、道达尔（盘前）、 Shopify（盘前）、思科（盘后）；2月12日有：猫途鹰（盘前）、凯悦酒店（盘前）、应用材料（盘 后）、淡水河谷（盘后）、Coinbase（盘后）、Rivia ...

Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns. While those clinical-stage biotech stocks can offer enormous upside, they also come with outsized risk. However, sometimes established biotech companies like Gilead Sciences (GILD), which can deliver steadier and sometimes surprising growth, are overlooked. GILD stock has surged 22% so far this year, outperforming the broader market gain. As Gilead prepares to report its fourth-q ...

Key Takeaways GILD reports Q4 results on Feb. 10, with consensus estimates of $7.57B in sales and $1.83 in EPS.Gilead's HIV franchise remains the growth engine, led by Biktarvy, Descovy and contributions from Yeztugo.GILD faces pressure in cell therapy sales, while liver disease drugs and Trodelvy support revenues.Biotech bigwig Gilead Sciences, Inc. (GILD) is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, after market close. The Zacks Consensus Estimate for fourth-quarter sales a ...

Key Takeaways GILD stock rose 20.8% in a month after NEJM published positive phase III ASCENT-04 results in metastatic TNBC.GILD's Trodelvy with Keytruda cut progression or death risk by 35% and lifted median PFS to 11.2 months.GILD data support a new first-line PD-L1 TNBC standard, backing submitted filings to expand Trodelvy's label.Shares of Gilead Sciences, Inc. (GILD) have gained 20.8% in a month compared with the industry’s growth of 4.5%.Much of this rally followed the Jan. 21 announcement that full ...

We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. 5 Countries With Highest Rates of AIDS BlurryMe/Shutterstock.com Gilead Sciences (GILD), historically a leader in HIV and hepatitis C treatments, is now positioning onco ...

Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as one of the most profitable stocks on NASDAQ, with recent price target increases from Truist Securities and Citigroup indicating strong investor confidence in the company's future performance [1][3]. Group 1: Price Target Adjustments - Truist Securities raised its price target on Gilead Sciences to $145 from $140 while maintaining a Buy rating, citing revisions in estimates for the drug YEZTUGO and updates on upcoming launches [2]. - Citigroup also increased its price target for Gilead Sciences to $156 from $140, maintaining a Buy rating, as part of a broader Q4 preview for biopharmaceutical stocks [3]. Group 2: Company Overview - Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer [4].

Atle Fund Management AB grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 78,169 shares of the biopharmaceutical company’s stock after buying an additional 5,004 shares during the period. Gilead Sciences accounts for about 3.4% of Atle Fund Management AB’s investment portfolio, making the stock its 10th biggest holding. Atle ...

Company Overview - Gilead Sciences, Inc. is a California-based biopharmaceutical company founded in 1987, specializing in medicines aimed at unmet needs, including treatments for HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension, and serious invasive fungal infections [4] Investment Ratings and Price Targets - UBS raised the price target on Gilead Sciences from $145 to $155, maintaining a Buy rating, which implies nearly a 12% upside from the current price [1] - BMO Capital also increased its target on Gilead Sciences to $150 from $135, reiterating an Outperform rating, and highlighted the strong momentum in the company's HIV business and the successful launch of Yeztugo, which is projected to achieve $150 million in FY25 sales [3] Industry Insights - The U.S. Pharmaceuticals and Biotechnology group is expected to perform strongly due to appealing valuations, light positioning, and sustained pharma-led M&A activity, despite concerns regarding conservative guidance [2]

Dow Jones Leader Amgen Leads These Biotechs Heading Into O4 Earnings | Investor's Business DailyBREAKING: [Trump Names Warsh New Fed Chairman] --- Biotech stocks continue to outperform in the current stock market rally, as Dow Jones index component and industry giant Amgen (AMGN), alone with Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Argenx (ARGX) trade in or near buy zones. Fourth-quarter earnings season is kicking into full swing, which will spur stock mar ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $173.3 billion by market cap, the company’s primary areas of focus include HIV, AIDS, liver disease, and serious cardiovascular and respiratory conditions. Shares of this HIV giant have outperformed the broader market over the past year. GILD has gained 48.9% over this time frame, while the broader S&P 5 ...